Literature DB >> 6629596

Remission of rheumatoid arthritis and other disorders of immunity in patients taking monoamine oxidase inhibitors.

J Lieb.   

Abstract

Elevated levels of prostaglandin E2 (PGE2) play an important role in rheumatoid arthritis and other disorders of immunity. By inhibiting the release of arachidonic acid from cells, monoamine oxidase inhibitors (MAOI's) inhibit PGE2 synthesis. MAOI's appear to be capable of remitting the symptoms of rheumatoid arthritis and may have the potential to arrest it. MAOI's also appear to be effective in other disturbances of immunity in which excessive synthesis of PGE2 plays a role.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6629596     DOI： 10.1016/0192-0561(83)90039-5

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN： 0192-0561


  10 in total

Review 1.  Psychiatric comorbidity in the treatment of patients with inflammatory bowel disease.

Authors:  Branislav R Filipovic; Branka F Filipovic
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

2.  Repurposing monoamine oxidase inhibitors (MAOI) for the treatment of rheumatoid arthritis possibly through modulating reactive oxidative stress mediated inflammatory cytokines.

Authors:  Debjeet Sur; Arpan Dutta; Chaitali Mondal; Apurba Banerjee; Pallab Kanti Haldar; Himangshu Sekhar Maji; Asis Bala
Journal:  Inflammopharmacology       Date:  2022-03-10       Impact factor: 4.473

Review 3.  The dopamine transporter: An unrecognized nexus for dysfunctional peripheral immunity and signaling in Parkinson's Disease.

Authors:  Phillip Mackie; Joe Lebowitz; Leila Saadatpour; Emily Nickoloff; Peter Gaskill; Habibeh Khoshbouei
Journal:  Brain Behav Immun       Date:  2018-03-15       Impact factor: 7.217

4.  Lipopolysaccharide-induced epithelial monoamine oxidase mediates alveolar bone loss in a rat chronic wound model.

Authors:  Daisuke Ekuni; James D Firth; Tarun Nayer; Takaaki Tomofuji; Toshihiro Sanbe; Koichiro Irie; Tatsuo Yamamoto; Takashi Oka; Zhenzi Liu; Juergen Vielkind; Edward E Putnins
Journal:  Am J Pathol       Date:  2009-09-24       Impact factor: 4.307

5.  Defeating cancer with antidepressants.

Authors:  J Lieb
Journal:  Ecancermedicalscience       Date:  2008-08-21

6.  Deprenyl reduces inflammation during acute SIV infection.

Authors:  K M Emanuel; K Runner; Z D Brodnik; B M Morsey; B G Lamberty; H S Johnson; A Acharya; S N Byrareddy; R A España; H S Fox; P J Gaskill
Journal:  iScience       Date:  2022-04-06

7.  Antidepressants and inflammatory bowel disease: a systematic review.

Authors:  Antonina A Mikocka-Walus; Deborah A Turnbull; Nicole T Moulding; Ian G Wilson; Jane M Andrews; Gerald J Holtmann
Journal:  Clin Pract Epidemiol Ment Health       Date:  2006-09-20

8.  Inhibiting peripheral and central MAO-B ameliorates joint inflammation and cognitive impairment in rheumatoid arthritis.

Authors:  Woojin Won; Hyun-Ji Choi; Ji-Young Yoo; Daeun Kim; Tai Young Kim; YeonHa Ju; Ki Duk Park; Hyunbeom Lee; Sang Youn Jung; C Justin Lee
Journal:  Exp Mol Med       Date:  2022-08-18       Impact factor: 12.153

9.  Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance.

Authors:  Matteo Martino; Giulio Rocchi; Andrea Escelsior; Michele Fornaro
Journal:  Curr Neuropharmacol       Date:  2012-06       Impact factor: 7.363

10.  The evaluation of 1-tetralone and 4-chromanone derivatives as inhibitors of monoamine oxidase.

Authors:  Stephanus J Cloete; Clarina I N'Da; Lesetja J Legoabe; Anél Petzer; Jacobus P Petzer
Journal:  Mol Divers       Date:  2020-09-24       Impact factor: 2.943
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.